Author

R. Rais

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Assay:metabolomics· 1

Frequent Co-Authors

B. S. Slusher· 3 shared J. D. Powell· 2 shared L. Zhao· 2 shared P. Majer· 2 shared A. Amor-Coarasa· 1 shared A. J. Tam· 1 shared A. Nikolopoulou· 1 shared B. Koleske· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

B. S. Slusher

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis

S. Parveen, J. Shen, S. Lun, L. Zhao, B. Koleske, R. D. Leone, R. Rais, J. D. Powell, J. R. Murphy, B. S. Slusher, W. R. Bishai

This study shows that JHU083, a glutamine metabolism inhibitor, reduces Mtb growth and modulates host immunity in tuberculosis, with effects dependent on host factors.

bioRxiv · Feb 23, 2023 · PreprintMicrobiology

Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation of MDSCs and reprogramming tumor associated macrophages

M.-H. Oh, I.-H. Sun, L. Zhao, R. Leone, I.-M. Sun, W. Xu, S. L. Collins, A. J. Tam, R. L. Blosser, C. H. Patel, J. Englert, M. L. Arwood, J. Wen, Y. Chan-Li, P. Majer, , J. D. Powell

This study shows that targeting glutamine metabolism in tumors reduces MDSC generation, increases inflammatory macrophages, and enhances anti-tumor immunity, making checkpoint-resistant tumors responsive to immunotherapy.

bioRxiv · Jun 3, 2019 · PreprintImmunology

JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy

M. T. Nedelcovych, R. P. Dash, Y. Wu, E. Y. Choi, R. S. Lapidus, P. Majer, D. Abou, M.-F. Penet, A. Nikolopoulou, A. Amor-Coarasa, J. Babich, D. L. Thorek, R. Rais, C. Kratochwil, B. S. Slusher

This paper describes the development of JHU-2545, a prodrug that selectively shields salivary glands and kidneys from PSMA-targeted radiotherapy, improving safety without affecting tumor uptake.

bioRxiv · Feb 15, 2019 · PreprintPharmacology & Toxicology